IN2014DN11027A - - Google Patents

Info

Publication number
IN2014DN11027A
IN2014DN11027A IN11027DEN2014A IN2014DN11027A IN 2014DN11027 A IN2014DN11027 A IN 2014DN11027A IN 11027DEN2014 A IN11027DEN2014 A IN 11027DEN2014A IN 2014DN11027 A IN2014DN11027 A IN 2014DN11027A
Authority
IN
India
Prior art keywords
compound
treatment
subunit
disorders
responsive
Prior art date
Application number
Other languages
English (en)
Inventor
Janus Schreiber Larsen
Magnus Gustafsson
Carsten Jessen
Original Assignee
Aniona Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aniona Aps filed Critical Aniona Aps
Publication of IN2014DN11027A publication Critical patent/IN2014DN11027A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
IN11027DEN2014 2012-06-26 2013-06-25 IN2014DN11027A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664288P 2012-06-26 2012-06-26
DKPA201270369 2012-06-26
PCT/EP2013/063194 WO2014001282A1 (en) 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
IN2014DN11027A true IN2014DN11027A (de) 2015-09-25

Family

ID=49782300

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11027DEN2014 IN2014DN11027A (de) 2012-06-26 2013-06-25

Country Status (13)

Country Link
US (2) US9475797B2 (de)
EP (1) EP2885290B1 (de)
JP (1) JP6223443B2 (de)
KR (1) KR20150033679A (de)
CN (1) CN104411703A (de)
AU (1) AU2013283488A1 (de)
BR (1) BR112014032501A2 (de)
CA (1) CA2876780A1 (de)
IL (1) IL235991A (de)
IN (1) IN2014DN11027A (de)
MX (1) MX2014014872A (de)
RU (1) RU2014149123A (de)
WO (1) WO2014001282A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物
JP2023525130A (ja) * 2020-05-13 2023-06-14 エフ. ホフマン-ラ ロシュ アーゲー Gaba a alpha5 pamとしての新規トリアゾリル誘導体
HUP2100338A1 (hu) 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196181T3 (es) 1995-11-01 2003-12-16 Novartis Ag Derivados de purina y proceso para su preparacion.
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
EP1042299A1 (de) 1997-12-22 2000-10-11 Du Pont Pharmaceuticals Company Stickstoffenthaltende heteroaromaten mit ortho-substituierten p1 gruppen als faktor-xa-inhibitoren
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
ATE327242T1 (de) 1999-12-17 2006-06-15 Ariad Pharma Inc Neue purine
JP2003531111A (ja) 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
EP1244679B1 (de) 1999-12-17 2006-11-15 Ariad Pharmaceuticals, Inc. Purinderivate
GB2378180B8 (en) 2001-06-27 2009-10-21 Cyclacel Ltd New purine derivatives
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
US7176312B2 (en) 2001-10-12 2007-02-13 The Scripps Research Institute Kinase inhibitor scaffolds and methods for their preparation
US20030229105A1 (en) 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003265636A1 (en) 2002-09-06 2004-03-29 Smithkline Beecham Corporation Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds
AU2004264419B2 (en) 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
JPWO2005080377A1 (ja) 2004-02-20 2007-10-25 キリンホールディングス株式会社 TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0407723D0 (en) 2004-04-05 2004-05-12 Novartis Ag Organic compounds
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
NZ556248A (en) 2005-03-14 2010-06-25 Neurosearch As Pyrazolyl-quinazoline potassium channel modulating agents and their medical use
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
JP2008540685A (ja) 2005-05-19 2008-11-20 シーブイ・セラピューティクス・インコーポレイテッド A1アデノシンレセプターアゴニスト
AU2006298867A1 (en) 2005-09-19 2007-04-12 F. Hoffmann-La Roche Ag Isoxazolo derivatives as GABA A alpha5 inverse agonists
WO2007042420A1 (en) 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
JP2009514924A (ja) 2005-11-09 2009-04-09 エフ.ホフマン−ラ ロシュ アーゲー 3−アリール−イソオキサゾール−4−カルボニル−ベンゾフラン誘導体
WO2007071632A2 (en) 2005-12-20 2007-06-28 Neurosearch A/S 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
RU2426731C2 (ru) 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
US7399769B2 (en) 2005-12-27 2008-07-15 Hoffmann-La Roche Inc. Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
RU2425045C2 (ru) 2005-12-27 2011-07-27 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазол-4-ил-имидазола
BRPI0711875A2 (pt) * 2006-05-24 2012-01-10 Lilly Co Eli compostos e métodos para modular os fxr
EP2029559B1 (de) 2006-05-31 2009-08-05 F. Hoffmann-Roche AG Aryl-4-ethinylisoxazolderivate
EP1894924A1 (de) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterozyklische FXR Bindungsverbindungen
EP1894928A1 (de) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Fxr bindende heterocyclische verbindungen
US20110144140A1 (en) 2006-09-07 2011-06-16 Eriksen Birgitte L Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
US8222262B2 (en) 2006-10-03 2012-07-17 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
EP2124954A2 (de) 2007-01-26 2009-12-02 Irm Llc Purinverbindungen und zusammensetzungen als kinasehemmer zur behandlung von mit plasmodium in zusammenhang stehenden erkrankungen
EP2114916A2 (de) 2007-02-02 2009-11-11 NeuroSearch A/S Pyridinyl-pyrazol-derivate und deren verwendung als kaliumkanalmodulatoren
JP5703432B2 (ja) 2007-03-28 2015-04-22 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2142547A1 (de) 2007-03-28 2010-01-13 NeuroSearch A/S Purinylderivate und ihre verwendung als kaliumkanalmodulatoren
CN101965344B (zh) 2007-06-22 2013-03-06 弗·哈夫曼-拉罗切有限公司 异*唑-咪唑衍生物
AU2008313789A1 (en) 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine AL receptor ligands
WO2009071464A1 (en) 2007-12-04 2009-06-11 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
ES2531023T3 (es) 2007-12-04 2015-03-09 Hoffmann La Roche Derivados de isoxazolo-piridina
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2128158A1 (de) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclische Cyclopropyl-substituierte FXR-bindende Verbindungen
GEP20135957B (en) * 2008-06-19 2013-11-11 Takeda Pharmaceuticals Co Heterocyclic compound and usage thereof
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
EP2344501A1 (de) 2008-09-26 2011-07-20 NeuroSearch A/S Substituierte purinylpyrazolderivate und deren verwendung als kaliumkanalmodulatoren
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
EP2427456B1 (de) 2009-05-05 2020-02-05 F.Hoffmann-La Roche Ag Isoxazol-pyridin-derivate
WO2010127975A1 (en) 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
AU2010244545A1 (en) 2009-05-05 2011-10-13 F. Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
CA2759598C (en) 2009-05-05 2017-09-12 F. Hoffmann-La Roche Ag Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
MX2011011484A (es) 2009-05-07 2011-11-18 Hoffmann La Roche Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
EP2289883A1 (de) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4)
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
CA2815741A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives as ligands for gaba receptors
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds

Also Published As

Publication number Publication date
CA2876780A1 (en) 2014-01-03
IL235991A0 (en) 2015-02-01
MX2014014872A (es) 2015-08-06
EP2885290A1 (de) 2015-06-24
BR112014032501A2 (pt) 2017-06-27
US9884848B2 (en) 2018-02-06
US20170114045A1 (en) 2017-04-27
JP6223443B2 (ja) 2017-11-01
WO2014001282A1 (en) 2014-01-03
AU2013283488A1 (en) 2015-01-15
JP2015521643A (ja) 2015-07-30
EP2885290B1 (de) 2017-10-18
US20160115155A1 (en) 2016-04-28
CN104411703A (zh) 2015-03-11
US9475797B2 (en) 2016-10-25
KR20150033679A (ko) 2015-04-01
RU2014149123A (ru) 2016-08-20
IL235991A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
PH12014501900A1 (en) Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors
MD20150091A2 (ro) Compuşi antivirali
PH12016500094A1 (en) Autotaxin inhibitors
MX357504B (es) Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
IN2015DN00847A (de)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2014MN02459A (de)
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MD4583B1 (ro) Piridinone biciclice noi
JO3334B1 (ar) مشتقات أوكسازوليدين-2- أون – بيريميدين
IN2015DN00372A (de)
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
IN2014CN03854A (de)
PH12017500595B1 (en) Aldosterone synthase inhibitors
PH12017500089B1 (en) Aldosterone synthase inhibitors
IN2014DN11027A (de)
IN2013DN02555A (de)
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
WO2012174552A3 (en) Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
IN2014KN00849A (de)
AU2019268209A1 (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions
TN2014000340A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
LV14738A (lv) Kardiovaskulāras iedarbības preparāts
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production